Overview
Intraductal papillary mucinous neoplasms (IPMNs) are cystic neoplasms of the pancreas characterized by mucus-filled papillae projecting into the main or branch ducts, potentially progressing to invasive pancreatic cancer 1.Diagnosis
Imaging techniques including endoscopic ultrasound (EUS) and magnetic resonance imaging (MRI) are essential for diagnosis 1.
Endoscopic retrograde cholangiopancreatography (ERCP) with cytology may aid in diagnosis 1.
High-risk features include main duct involvement, solid component, and lymph node enlargement 1.
EUS-guided fine needle aspiration (EUS-FNA) can be indicated for further characterization 1.Management
Surveillance imaging for 5 years recommended for IPMNs with ≤one high-risk feature if no significant changes are noted 1.
Surveillance cessation after 5 years without significant changes is supported if no high-risk features worsen 1.
EUS-FNA may influence outcomes; its routine use is debated based on risk stratification 1.Special Populations
No specific guidelines provided for pregnancy, pediatrics, elderly, or comorbidities in the given abstracts 1.Key Recommendations
Conduct imaging surveillance for 5 years in patients with IPMNs and ≤one high-risk feature if there are no significant changes; discontinue surveillance if no progression noted (Evidence: Moderate) 1.
Consider EUS-FNA for risk stratification but recognize its impact on outcomes varies; tailor use based on clinical judgment (Evidence: Moderate) 1.
Monitor patients closely post-5 years surveillance period, with heightened vigilance for any new high-risk features (Evidence: Expert opinion) 1.References
1 Imbe K, Nagata N, Hisada Y, Takasaki Y, Sekine K, Mishima S et al.. Validation of the American Gastroenterological Association guidelines on management of intraductal papillary mucinous neoplasms: more than 5 years of follow-up. European radiology 2018. link